SEK 1.6
(0.25%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -438 Thousand SEK | 99.27% |
2022 | -60.17 Million SEK | -137.34% |
2021 | -25.35 Million SEK | 45.16% |
2020 | -46.23 Million SEK | -103.28% |
2019 | -22.74 Million SEK | -2.38% |
2018 | -22.21 Million SEK | -108.35% |
2017 | -10.66 Million SEK | -334.82% |
2016 | 4.54 Million SEK | 129.3% |
2015 | -15.5 Million SEK | -35.21% |
2014 | -11.46 Million SEK | -161.31% |
2013 | -4.38 Million SEK | -23.74% |
2012 | -3.54 Million SEK | -157.48% |
2011 | -1.37 Million SEK | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | -5.78 Million SEK | -88.31% |
2024 Q3 | -5.2 Million SEK | 9.96% |
2024 Q1 | -3.07 Million SEK | 39.08% |
2023 Q2 | -11.73 Million SEK | 4.35% |
2023 Q3 | 28.61 Million SEK | 343.96% |
2023 Q1 | -12.26 Million SEK | 17.15% |
2023 Q4 | -5.04 Million SEK | -117.62% |
2023 FY | -438 Thousand SEK | 99.27% |
2022 FY | -60.17 Million SEK | -137.34% |
2022 Q3 | -13 Million SEK | 26.35% |
2022 Q2 | -17.66 Million SEK | -25.97% |
2022 Q4 | -14.8 Million SEK | -13.79% |
2022 Q1 | -14.02 Million SEK | 6.76% |
2021 FY | -25.35 Million SEK | 45.16% |
2021 Q4 | -15.03 Million SEK | -185.6% |
2021 Q3 | 17.56 Million SEK | 226.25% |
2021 Q2 | -13.91 Million SEK | -1.61% |
2021 Q1 | -13.69 Million SEK | 5.7% |
2020 Q1 | -9.76 Million SEK | 11.39% |
2020 FY | -46.23 Million SEK | -103.28% |
2020 Q4 | -14.52 Million SEK | -142.62% |
2020 Q2 | -12.51 Million SEK | -28.11% |
2020 Q3 | -5.98 Million SEK | 52.15% |
2019 Q3 | -7.18 Million SEK | -260.0% |
2019 FY | -22.74 Million SEK | -2.38% |
2019 Q4 | -11.02 Million SEK | -53.33% |
2019 Q2 | 4.49 Million SEK | 157.44% |
2019 Q1 | -7.82 Million SEK | 27.49% |
2018 Q4 | -10.78 Million SEK | -21.07% |
2018 FY | -22.21 Million SEK | -108.35% |
2018 Q3 | -8.9 Million SEK | 7.66% |
2018 Q2 | -9.64 Million SEK | -235.44% |
2018 Q1 | 7.12 Million SEK | 199.0% |
2017 Q1 | 1.07 Million SEK | -60.92% |
2017 Q2 | 975 Thousand SEK | -9.47% |
2017 Q3 | -5.52 Million SEK | -666.26% |
2017 Q4 | -7.19 Million SEK | -30.3% |
2017 FY | -10.66 Million SEK | -334.82% |
2016 Q2 | 4.09 Million SEK | 244.83% |
2016 FY | 4.54 Million SEK | 129.3% |
2016 Q4 | 2.75 Million SEK | 430.99% |
2016 Q3 | 519 Thousand SEK | -87.31% |
2016 Q1 | -2.82 Million SEK | 29.63% |
2015 FY | -15.5 Million SEK | -35.21% |
2015 Q4 | -4.01 Million SEK | -53.88% |
2015 Q3 | -2.6 Million SEK | 48.25% |
2015 Q2 | -5.04 Million SEK | -31.28% |
2015 Q1 | -3.83 Million SEK | -3.15% |
2014 Q4 | -3.72 Million SEK | -37.79% |
2014 FY | -11.46 Million SEK | -161.31% |
2014 Q1 | -2.42 Million SEK | -217.12% |
2014 Q2 | -2.61 Million SEK | -7.79% |
2014 Q3 | -2.7 Million SEK | -3.29% |
2013 Q3 | -1.38 Million SEK | -23.1% |
2013 Q2 | -1.12 Million SEK | 0.0% |
2013 Q4 | -765 Thousand SEK | 44.57% |
2013 FY | -4.38 Million SEK | -23.74% |
2013 Q1 | -1.12 Million SEK | 0.0% |
2012 FY | -3.54 Million SEK | -157.48% |
2011 FY | -1.37 Million SEK | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Alligator Bioscience AB (publ) | -248.58 Million SEK | 99.824% |
Ziccum AB (publ) | -21.41 Million SEK | 97.954% |
Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 97.553% |
BioArctic AB (publ) | 229.24 Million SEK | 100.191% |
Mendus AB (publ) | -101.61 Million SEK | 99.569% |
Genovis AB (publ.) | 61.5 Million SEK | 100.712% |
Intervacc AB (publ) | -102.85 Million SEK | 99.574% |
QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 97.349% |
Active Biotech AB (publ) | -45.8 Million SEK | 99.044% |
Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 103.599% |
Bio-Works Technologies AB (publ) | -56.82 Million SEK | 99.229% |
Aptahem AB (publ) | -11.11 Million SEK | 96.059% |
Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 99.859% |
Kancera AB (publ) | -64.88 Million SEK | 99.325% |
Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 99.644% |
Fluicell AB (publ) | -26.55 Million SEK | 98.351% |
Saniona AB (publ) | -95.81 Million SEK | 99.543% |
Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 96.389% |
Biovica International AB (publ) | -124.82 Million SEK | 99.649% |
Spago Nanomedical AB (publ) | -42.22 Million SEK | 98.963% |
AcouSort AB (publ) | -17.08 Million SEK | 97.437% |
Xintela AB (publ) | -54.08 Million SEK | 99.19% |
Abliva AB (publ) | -95.5 Million SEK | 99.541% |
Egetis Therapeutics AB (publ) | -326.9 Million SEK | 99.866% |
Karolinska Development AB (publ) | 5.38 Million SEK | 108.132% |
OncoZenge AB (publ) | -15.9 Million SEK | 97.246% |
Amniotics AB (publ) | -30.87 Million SEK | 98.581% |
2cureX AB (publ) | -32.51 Million SEK | 98.653% |
CombiGene AB (publ) | -35.66 Million SEK | 98.772% |
Asarina Pharma AB (publ) | -12.82 Million SEK | 96.586% |
Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 99.906% |
Camurus AB (publ) | 431.44 Million SEK | 100.102% |
Corline Biomedical AB | -1.8 Million SEK | 75.788% |
IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 99.754% |
Isofol Medical AB (publ) | -37.07 Million SEK | 98.818% |
I-Tech AB | 20.2 Million SEK | 102.168% |
Hansa Biopharma AB (publ) | -831.72 Million SEK | 99.947% |
Cyxone AB (publ) | -22.98 Million SEK | 98.095% |
ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 99.521% |
Biosergen AB | -27.03 Million SEK | 98.38% |
Cantargia AB (publ) | -280.02 Million SEK | 99.844% |
NextCell Pharma AB | -41.95 Million SEK | 98.956% |
Xspray Pharma AB (publ) | -179.66 Million SEK | 99.756% |
Elicera Therapeutics AB (publ) | -16.39 Million SEK | 97.329% |
Nanologica AB (publ) | -75.15 Million SEK | 99.417% |
SynAct Pharma AB | -215.81 Million SEK | 99.797% |
Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 99.006% |
Stayble Therapeutics AB (publ) | -23.73 Million SEK | 98.155% |
LIDDS AB (publ) | -40.2 Million SEK | 98.911% |
Lipum AB (publ) | -37.17 Million SEK | 98.822% |
BioInvent International AB (publ) | -330.3 Million SEK | 99.867% |
Alzinova AB (publ) | -16.48 Million SEK | 97.342% |
Oncopeptides AB (publ) | -249.11 Million SEK | 99.824% |
Pila Pharma AB (publ) | -9.93 Million SEK | 95.589% |
Guard Therapeutics International AB (publ) | -113.32 Million SEK | 99.613% |
Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 97.923% |
Simris Alg AB (publ) | -37.3 Million SEK | 98.826% |
Diamyd Medical AB (publ) | -151.85 Million SEK | 99.712% |
Xbrane Biopharma AB (publ) | -388.17 Million SEK | 99.887% |
Ascelia Pharma AB (publ) | -109.28 Million SEK | 99.599% |
Diagonal Bio AB (publ) | -11.67 Million SEK | 96.249% |